Plain-English translation of NCT06664996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating a specific type of liver cancer called hepatocellular carcinoma. The study combines sintilimab (an immunotherapy drug that helps your immune system fight cancer) with stereotactic body radiation therapy (a precise, high-dose radiation focused on tumors) given before surgery. The goal is to shrink the cancer and make surgery safer and more effective.
Liver cancer with blood clots inside the liver vessels is difficult to treat and has limited options. Researchers believe that using this medication before surgery might help prepare the body to fight remaining cancer cells and improve survival after the operation.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy on three separate days over one week, combined with two doses of the medication given about three weeks apart. Eight weeks after starting treatment, you would have surgery to remove the cancer. After surgery, you would continue the medication every three weeks for six months. Throughout the study, you would have regular imaging tests and blood work, with follow-up visits every three months for one year to monitor your health and recovery.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China